Derm VOA
AAD 2026视频特辑
抗HER2新答案——从耐药困境到完全缓解:泽尼达妥单抗后线治疗HER2阳性晚期胆管癌,6个月实现CR
ONCO前沿 | 2026-11-03
Copyright (C) 2026 by eDoctor Healthcare Communications. All Rights Reserved.
沪公网安备31010502003091号 | 沪ICP备11005620号-15